Compare GCTS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | ADCT |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.8M | 192.7M |
| IPO Year | 2021 | 2019 |
| Metric | GCTS | ADCT |
|---|---|---|
| Price | $1.11 | $1.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.13 | ★ $3.33 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | $2,866,000.00 | ★ $81,357,000.00 |
| Revenue This Year | $76.29 | N/A |
| Revenue Next Year | $648.00 | $25.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $0.96 | $0.78 |
| 52 Week High | $3.93 | $4.98 |
| Indicator | GCTS | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 42.55 |
| Support Level | $1.00 | $0.97 |
| Resistance Level | $1.43 | $1.45 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 23.83 | 8.80 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).